{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:16:57Z","timestamp":1777425417877,"version":"3.51.4"},"reference-count":90,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research Agency","doi-asserted-by":"publisher","award":["P3-0171"],"award-info":[{"award-number":["P3-0171"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Currently, there is no cure for Alzheimer\u2019s disease (AD) in humans; treatment is symptomatic only. Aging of the population, together with an unhealthy diet and lifestyle, contribute to the steady, global increase of AD patients. This increase creates significant health, societal and economical challenges even for the most developed countries. AD progresses from an asymptomatic stage to a progressively worsening cognitive impairment. The AD cognitive impairment is underpinned by progressive memory impairment, an increasing inability to recall recent events, to execute recently planned actions, and to learn. These changes prevent the AD patient from leading an independent and fulfilling life. Nanotechnology (NT) enables a new, alternative pathway for development of AD treatment interventions. At present, the NT treatments for attenuation of AD memory impairment are at the animal model stage. Over the past four years, there has been a steady increase in publications of AD animal models with a wide variety of original NT treatment interventions, able to attenuate memory impairment. NT therapy development, in animal models of AD, is faced with the twin challenges of the nature of AD, a chronic impairment, unique to human, of the tau protein and A \u03b2 peptides that regulate several key physiological brain processes, and the incomplete understanding of AD\u2032s aetiology. This paper reviews the state-of-the-art in NT based treatments for AD memory impairment in animal models and discusses the future work for translation to the successful treatment of AD cognitive impairment in human.<\/jats:p>","DOI":"10.3390\/ijms22031102","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T11:13:53Z","timestamp":1611314033000},"page":"1102","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nanotechnology Therapy for Alzheimer\u2032s Disease Memory Impairment Attenuation"],"prefix":"10.3390","volume":"22","author":[{"given":"Samo","family":"Ribari\u010d","sequence":"first","affiliation":[{"name":"Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5455\/ajrms.20180717105137","article-title":"Interaction of nanoparticles with central nervous system and its consequences","volume":"4","author":"Athira","year":"2018","journal-title":"Am. J. Res. Med. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Teleanu, D.M., Chircov, C., Grumezescu, A.M., Volceanov, A., and Teleanu, R.I. (2018). Impact of nanoparticles on brain health: An up to date overview. J. Clin. Med., 7.","DOI":"10.3390\/jcm7120490"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.tibtech.2017.06.002","article-title":"Advances in alzheimer\u2019s diagnosis and therapy: The implications of nanotechnology","volume":"35","author":"Hajipour","year":"2017","journal-title":"Trends Biotechnol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijbiomac.2019.02.156","article-title":"Nanoparticle formulations in the diagnosis and therapy of alzheimer\u2019s disease","volume":"130","author":"Gupta","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_7","first-page":"4981","article-title":"Nanotechnology-based drug delivery systems for the treatment of alzheimer\u2019s disease","volume":"10","author":"Gremiao","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"de la Torre, C., and Cena, V. (2018). The delivery challenge in neurodegenerative disorders: The nanoparticles role in alzheimer\u2019s disease therapeutics and diagnostics. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10040190"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wong, K.H., Riaz, M.K., Xie, Y.N., Zhang, X., Liu, Q., Chen, H.J., Bian, Z.X., Chen, X.Y., Lu, A.P., and Yang, Z.J. (2019). Review of current strategies for delivering alzheimer\u2019s disease drugs across the blood-brain barrier. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020381"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Greish, K., Alqahtani, A.A., Alotaibi, A.F., Abdulla, A.M., Bukelly, A.T., Alsobyani, F.M., Alharbi, G.H., Alkiyumi, I.S., Aldawish, M.M., and Alshahrani, T.F. (2019). The effect of silver nanoparticles on learning, memory and social interaction in balb\/c mice. Int. J. Env. Res. Public Health, 16.","DOI":"10.3390\/ijerph16010148"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/acschemneuro.7b00312","article-title":"Sulfur nanoparticles with novel morphologies coupled with brain-targeting peptides rvg as a new type of inhibitor against metal-induced abeta aggregation","volume":"9","author":"Sun","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e1807965","DOI":"10.1002\/adma.201807965","article-title":"Magnetite\/ceria nanoparticle assemblies for extracorporeal cleansing of amyloid-beta in alzheimer\u2019s disease","volume":"31","author":"Kim","year":"2019","journal-title":"Adv. Mater."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1021\/acsnano.7b07625","article-title":"Tau-targeted multifunctional nanocomposite for combinational therapy of alzheimer\u2019s disease","volume":"12","author":"Chen","year":"2018","journal-title":"ACS Nano"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40824-019-0166-x","article-title":"Therapeutic efficacy of nanoparticles and routes of administration","volume":"23","author":"Chenthamara","year":"2019","journal-title":"Biomater. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3389\/fnins.2018.01019","article-title":"Transcytosis to cross the blood brain barrier, new advancements and challenges","volume":"12","author":"Pulgar","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/17425247.2019.1583205","article-title":"Blood-brain barrier receptors and transporters: An insight on their function and how to exploit them through nanotechnology","volume":"16","author":"Moura","year":"2019","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000363702","article-title":"The neurobiological bases of memory formation: From physiological conditions to psychopathology","volume":"47","author":"Bisaz","year":"2014","journal-title":"Psychopathology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"a005751","DOI":"10.1101\/cshperspect.a005751","article-title":"Synapses and memory storage","volume":"4","author":"Mayford","year":"2012","journal-title":"Cold. Spring. Harb. Perspect. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fnagi.2018.00118","article-title":"The physiological roles of amyloid-beta peptide hint at new ways to treat alzheimer\u2019s disease","volume":"10","author":"Brothers","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_20","first-page":"613","article-title":"Memory dysfunction","volume":"21","author":"Matthews","year":"2015","journal-title":"Continuum"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12017-009-8109-7","article-title":"Functional alterations in memory networks in early alzheimer\u2019s disease","volume":"12","author":"Sperling","year":"2010","journal-title":"Neuromol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1212\/01.wnl.0000271376.19515.c6","article-title":"Spatial cognition and the human navigation network in ad and mci","volume":"69","author":"Rankin","year":"2007","journal-title":"Neurology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","article-title":"Alzheimer\u2019s disease: Experimental models and reality","volume":"133","author":"Drummond","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000090733","article-title":"An estimate of the worldwide prevalence and direct costs of dementia in 2003","volume":"21","author":"Wimo","year":"2006","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/jamaneurol.2019.0648","article-title":"Association of early-onset alzheimer disease with elevated low-density lipoprotein cholesterol levels and rare genetic coding variants of apob","volume":"76","author":"Wingo","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_26","first-page":"S10","article-title":"Gene-environment interaction in late-onset alzheimer disease: The role of apolipoprotein-epsilon4","volume":"12","author":"Mayeux","year":"1998","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ajhb.20516","article-title":"Apolipoprotein e polymorphism and neuronal plasticity","volume":"18","author":"Bufill","year":"2006","journal-title":"Am. J. Hum. Biol."},{"key":"ref_28","first-page":"445","article-title":"Memory loss in alzheimer\u2019s disease","volume":"15","author":"Holger","year":"2013","journal-title":"Clin. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0197-4580(00)00250-5","article-title":"Life span and synapses: Will there be a primary senile dementia?","volume":"22","author":"Terry","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1002\/hbm.23695","article-title":"A neuroimaging approach to capture cognitive reserve: Application to alzheimer\u2019s disease","volume":"38","author":"Wink","year":"2017","journal-title":"Hum. Brain Mapp."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40199-018-0221-5","article-title":"Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in alzheimer\u2019s disease animal model by reducing tau hyperphosphorylation","volume":"26","author":"Vakilinezhad","year":"2018","journal-title":"DARU"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijpharm.2017.07.080","article-title":"Anti-alzheimer\u2019s potential of berberine using surface decorated multi-walled carbon nanotubes: A preclinical evidence","volume":"530","author":"Lohan","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bfopcu.2016.10.004","article-title":"Quercetin nanoparticles attenuates scopolamine induced spatial memory deficits and pathological damages in rats","volume":"55","author":"Palle","year":"2017","journal-title":"Bull. Fac. Pharm. Cairo Univ. Cairo Univ."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3389\/fnagi.2018.00244","article-title":"Egcg nanoparticles attenuate aluminum chloride induced neurobehavioral deficits, beta amyloid and tau pathology in a rat model of alzheimer\u2019s disease","volume":"10","author":"Singh","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2019.01.008","article-title":"Reassembly of native components with donepezil to execute dual-missions in alzheimer\u2019s disease therapy","volume":"296","author":"Zhang","year":"2019","journal-title":"J. Control Release"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"146325","DOI":"10.1016\/j.brainres.2019.146325","article-title":"Neuroprotective effects of curcumin lipid-core nanocapsules in a model alzheimer\u2019s disease induced by beta-amyloid 1-42 peptide in aged female mice","volume":"1721","author":"Giacomeli","year":"2019","journal-title":"Brain Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12951-018-0356-z","article-title":"Memantine loaded plga pegylated nanoparticles for alzheimer\u2019s disease: In vitro and in vivo characterization","volume":"16","author":"Ettcheto","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.nano.2019.01.010","article-title":"Poly(propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection","volume":"17","author":"Aso","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2019.03.010","article-title":"Dual-drug loaded nanoparticles of epigallocatechin-3-gallate (egcg)\/ascorbic acid enhance therapeutic efficacy of egcg in a appswe\/ps1de9 alzheimer\u2019s disease mice model","volume":"301","author":"Cano","year":"2019","journal-title":"J. Control Release"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.2147\/IJN.S171490","article-title":"Ppargamma agonist-loaded plga-peg nanocarriers as a potential treatment for alzheimer\u2019s disease: In vitro and in vivo studies","volume":"13","author":"Calpena","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.biomaterials.2018.12.027","article-title":"Progressive release of mesoporous nano-selenium delivery system for the multi-channel synergistic treatment of alzheimer\u2019s disease","volume":"197","author":"Sun","year":"2019","journal-title":"Biomaterials"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijpharm.2017.04.033","article-title":"Dual-functional nanoparticles for precise drug delivery to alzheimer\u2019s disease lesions: Targeting mechanisms, pharmacodynamics and safety","volume":"525","author":"Zheng","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"13252","DOI":"10.1038\/s41598-019-49731-8","article-title":"Plasmon-activated water reduces amyloid burden and improves memory in animals with alzheimer\u2019s disease","volume":"9","author":"Cheng","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e12787","DOI":"10.1111\/cpr.12787","article-title":"Treatment of alzheimer\u2019s disease with framework nucleic acids","volume":"53","author":"Shao","year":"2020","journal-title":"Cell Prolif."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1038\/s41467-020-18525-2","article-title":"Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of alzheimer\u2019s disease","volume":"11","author":"Hou","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s13346-018-0570-0","article-title":"Curcumin-loaded self-nanomicellizing solid dispersion system: Part ii: In vivo safety and efficacy assessment against behavior deficit in alzheimer disease","volume":"8","author":"Parikh","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1016\/j.biomaterials.2009.02.051","article-title":"Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein rvg29 nanoparticles","volume":"30","author":"Liu","year":"2009","journal-title":"Biomaterials"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/s41467-018-04255-z","article-title":"A self-destructive nanosweeper that captures and clears amyloid beta-peptides","volume":"9","author":"Luo","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jtemb.2017.12.006","article-title":"Reduced plaque size and inflammation in the app23 mouse model for alzheimer\u2019s disease after chronic application of polymeric nanoparticles for cns targeted zinc delivery","volume":"49","author":"Vilella","year":"2018","journal-title":"J. Trace. Elem. Med. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.nano.2017.12.006","article-title":"Antibody-functionalized polymer nanoparticle leading to memory recovery in alzheimer\u2019s disease-like transgenic mouse model","volume":"14","author":"Carradori","year":"2018","journal-title":"Nanomedicine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"107082","DOI":"10.1016\/j.nlm.2019.107082","article-title":"Improvement of memory deficits in the rat model of alzheimer\u2019s disease by erythropoietin-loaded solid lipid nanoparticles","volume":"166","author":"Dara","year":"2019","journal-title":"Neurobiol. Learn. Mem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1021\/acschemneuro.8b00622","article-title":"Impact of gold nanoparticles on amyloid beta-induced alzheimer\u2019s disease in a rat animal model: Involvement of stim proteins","volume":"10","author":"Sanati","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s43440-019-00017-w","article-title":"Diphtheria toxoid nanoparticles improve learning and memory impairment in animal model of alzheimer\u2019s disease","volume":"72","author":"Heydari","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.biopha.2017.11.047","article-title":"Neuroprotective effect of hesperetin and nano-hesperetin on recognition memory impairment and the elevated oxygen stress in rat model of alzheimer\u2019s disease","volume":"97","author":"Kheradmand","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"117861","DOI":"10.1016\/j.lfs.2020.117861","article-title":"Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced alzheimer\u2019s disease model","volume":"255","author":"Saffari","year":"2020","journal-title":"Life Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.nano.2019.02.004","article-title":"Vitamin d-binding protein-loaded plga nanoparticles suppress alzheimer\u2019s disease-related pathology in 5xfad mice","volume":"17","author":"Jeon","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41593-019-0352-0","article-title":"In vivo neuronal gene editing via crispr-cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of alzheimer\u2019s disease","volume":"22","author":"Park","year":"2019","journal-title":"Nat. Neurosci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S1474-4422(14)70136-X","article-title":"Potential for primary prevention of alzheimer\u2019s disease: An analysis of population-based data","volume":"13","author":"Norton","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.archger.2009.09.035","article-title":"Life expectancy in alzheimer\u2019s disease (ad)","volume":"49","author":"Zanetti","year":"2009","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/brain\/awt062","article-title":"Brain amyloid-beta oligomers in ageing and alzheimer\u2019s disease","volume":"136","author":"Lesne","year":"2013","journal-title":"Brain"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13195-020-00636-z","article-title":"The dynamics of biomarkers across the clinical spectrum of alzheimer\u2019s disease","volume":"12","author":"Hadjichrysanthou","year":"2020","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_63","first-page":"205","article-title":"Predicting time to dementia using a quantitative template of disease progression","volume":"11","author":"Bilgel","year":"2019","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.neuroimage.2018.11.024","article-title":"Disease progression timeline estimation for alzheimer\u2019s disease using discriminative event based modeling","volume":"186","author":"Venkatraghavan","year":"2019","journal-title":"Neuroimage"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Huang, Y.R., and Liu, R.T. (2020). The toxicity and polymorphism of beta-amyloid oligomers. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124477"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: Structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnins.2018.00025","article-title":"Reconsideration of amyloid hypothesis and tau hypothesis in alzheimer\u2019s disease","volume":"12","author":"Kametani","year":"2018","journal-title":"Front. Neurosci-Switz."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12031-011-9566-7","article-title":"Are tangles as toxic as they look?","volume":"45","author":"Kopeikina","year":"2011","journal-title":"J. Mol. Neurosci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: Lessons from the alzheimer\u2019s amyloid beta-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nature.2016.21045","article-title":"Failed alzheimer\u2019s trial does not kill leading theory of disease","volume":"540","author":"Abbott","year":"2016","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3233\/JAD-2009-1092","article-title":"Why did tarenflurbil fail in alzheimer\u2019s disease?","volume":"17","author":"Imbimbo","year":"2009","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd4709","article-title":"Alzheimer antibody drugs show questionable potential","volume":"14","author":"Reardon","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: Few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","article-title":"Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant alzheimer\u2019s disease in the presenilin 1 e280a kindred: A case-control study","volume":"11","author":"Reiman","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nrd3869","article-title":"Drug repositioning for alzheimer\u2019s disease","volume":"11","author":"Corbett","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nm.3466","article-title":"Plasma phospholipids identify antecedent memory impairment in older adults","volume":"20","author":"Mapstone","year":"2014","journal-title":"Nat. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1093\/brain\/awl279","article-title":"Proteome-based plasma biomarkers for alzheimer\u2019s disease","volume":"129","author":"Hye","year":"2006","journal-title":"Brain"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3233\/JAD-140321","article-title":"Is amyloid-beta an innocent bystander and marker in alzheimer\u2019s disease? Is the liability of multivalent cation homeostasis and its influence on amyloid-beta function the real mechanism?","volume":"42","author":"ManafiRad","year":"2014","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.tips.2008.09.001","article-title":"Oxidative stress hypothesis in alzheimer\u2019s disease: A reappraisal","volume":"29","author":"Pratico","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4161\/oxim.2.2.7944","article-title":"Oxidative stress and anxiety: Relationship and cellular pathways","volume":"2","author":"Bouayed","year":"2009","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.3233\/JAD-179909","article-title":"Potential novel approaches to understand the pathogenesis and treat alzheimer\u2019s disease","volume":"64","author":"Drummond","year":"2018","journal-title":"J. Alzheimer\u2019s. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"22718","DOI":"10.3390\/molecules201219865","article-title":"Unfolded protein response and macroautophagy in alzheimer\u2019s, parkinson\u2019s and prion diseases","volume":"20","author":"Milisav","year":"2015","journal-title":"Molecules"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"11500","DOI":"10.1523\/JNEUROSCI.3203-08.2008","article-title":"Nicotinamide restores cognition in alzheimer\u2019s disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of thr231-phosphotau","volume":"28","author":"Green","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cell.2014.10.016","article-title":"Lessons from a failed gamma-secretase alzheimer trial","volume":"159","year":"2014","journal-title":"Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/d41586-018-05722-9","article-title":"The search for better animal models of alzheimer\u2019s disease","volume":"559","author":"King","year":"2018","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cpt.1434","article-title":"Pharmacodynamic drug-drug interactions","volume":"105","author":"Niu","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"18848","DOI":"10.1039\/C5NR05264E","article-title":"Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticles","volume":"7","author":"Kang","year":"2015","journal-title":"Nanoscale"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/3\/1102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:14:10Z","timestamp":1760159650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/3\/1102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":90,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["ijms22031102"],"URL":"https:\/\/doi.org\/10.3390\/ijms22031102","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]}}}